Vaping illnesses highlight unregulated e-cigarette market

With nearly 200 vaping-related lung disease injuries and one death across the U.S., the CDC’s investigation into e-cigarette harms is highlighting just how unregulated the market is for these relatively new tobacco and marijuana products, Politico reported.

So far, there have been no product recalls or other broad, public awareness campaigns to warn against the dangers of e-cigarette use, Politico noted, and there are scant details on the specifics of what’s causing the illness besides a link to vaping. And officials in the investigation don’t have much to go on, with few connections between the illnesses and, in some cases, an unlabeled plastic vaping tube.

The illnesses come after the FDA pushed back a review of e-cigarettes from 2017 to 2022, according to Politico, and no legal e-cigarette brands have undergone review as new products, flavors and varieties continue to hit store shelves. One e-cigarette company in particular, Juul, has come under fire for releasing fruity vaping flavors seemingly targeted toward teenagers.

The CDC is also reportedly considering a national alert.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.